Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906908 | 0.92 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL4814954 | 0.82 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL2497282 | 0.81 | — | — | |
| SCHEMBL48583 | 0.81 | — | — | |
| SCHEMBL13155617 | 0.80 | DRD2 (0.39) | — | |
| SCHEMBL2016344 | 0.79 | HRH3 (0.36) | KDM4EALDH1A1GAAKMT2ATSHR | |
| Bromide SCHEMBL2350294 | 0.79 | CARM1 (0.32) | KDM4EALDH1A1KMT2A | |
| SCHEMBL19361708 | 0.77 | DAO (0.33) | KDM4ETDP1ALDH1A1 | |
| SCHEMBL13156005 | 0.77 | ALOX15 (0.56) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13388851 | 0.77 | GNAI3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-1867667-B1 | Method for manufacturing stabilized polyacetal resin | POLYPLASTICS CO (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-8138305-B2 | Glucagon-like peptide-1 (glp-1) receptor agonist; diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease. | IPSEN PHARMA S.A.S. (FR) | 2012-03-20 | — | — | US | disclosed |
| US-7977455-B2 | Analogues of GLP-1 | IPSEN PHARMA, S.A.S. (FR) | 2011-07-12 | — | — | US | disclosed |
| US-7897566-B2 | Analogues of GLP-1 | IPSEN PHARMA S.A.S. (FR) | 2011-03-01 | — | — | US | disclosed |
| US-20100093685-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. | 2010-04-15 | — | — | US | disclosed |
| US-20090197802-A1 | Analogues of GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-06 | — | — | US | disclosed |
| US-20080271381-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | POLYPLASTICS CO., LTD (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080108566-A1 | Analogues of GLP-1 | IPSEN PHARMA S.A.S. (FR) | 2008-05-08 | — | — | US | disclosed |
| EP-1867667-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | Polyplastics Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-7268213-B2 | Analogues of GLP-1 | SOCIETE DE CONSELIS DE RECHERCHES ET D'APPLICATIONS SCIENTITIQUES, S.A.S. (FR) | 2007-09-11 | — | — | US | disclosed |
| US-7235628-B2 | Analogues of GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2007-06-26 | — | — | US | disclosed |
| US-20070042952-A1 | Analogues of glp-1 | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197802-A1 | Analogues of GLP-1 | GLP1R, IAPP, GIPR | KDM4E 3870/4885TDP1 2720/4885CHRNA7 2972/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | KDM4E 1251/4885TDP1 2606/4885CHRNA7 4382/4885 |
| US-20070042952-A1 | Analogues of glp-1 | GLP1R, IAPP, GIPR | KDM4E 4355/4885TDP1 2492/4885CHRNA7 2462/4885 |
| US-20080108566-A1 | Analogues of GLP-1 | GLP1R, IAPP, GIPR | KDM4E 3870/4885TDP1 2720/4885CHRNA7 2972/4885 |
| US-20100093685-A1 | NITRIC OXIDE RELEASING STEROIDS | NR3C1, CYP11B1, NOS1 | KDM4E 3494/4885TDP1 3038/4885CHRNA7 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.